325 related articles for article (PubMed ID: 25814008)
21. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
22. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
[TBL] [Abstract][Full Text] [Related]
25. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
26. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study.
Kawai S; Yokota T; Onozawa Y; Hamauchi S; Fukutomi A; Ogawa H; Onoe T; Onitsuka T; Yurikusa T; Todaka A; Tsushima T; Yoshida Y; Kito Y; Mori K; Yasui H
BMC Cancer; 2017 Jan; 17(1):59. PubMed ID: 28095814
[TBL] [Abstract][Full Text] [Related]
28. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
Tang WH; Sun W; Long GX
Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
[TBL] [Abstract][Full Text] [Related]
29. Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.
Rambeau A; Gervais R; De Raucourt D; Babin E; Dugué AE; Florescu C; Blanchard D; Gery B
Eur Arch Otorhinolaryngol; 2017 Jul; 274(7):2883-2889. PubMed ID: 28382396
[TBL] [Abstract][Full Text] [Related]
30. Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
León X; Agüero A; López M; García J; Farré N; López-Pousa A; Quer M
Auris Nasus Larynx; 2015 Apr; 42(2):145-9. PubMed ID: 25459494
[TBL] [Abstract][Full Text] [Related]
31. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
[TBL] [Abstract][Full Text] [Related]
32. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
Araki D; Redman MW; Martins R; Eaton K; Baik C; Chow L; Goulart B; Lee S; Santana-Davila R; Liao J; Parvathaneni U; Laramore G; Futran N; Mendez E; Bhrany A; Rodriguez CP
Head Neck; 2016 Sep; 38(9):1318-23. PubMed ID: 27061333
[TBL] [Abstract][Full Text] [Related]
33. Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer.
Bibault JE; Morelle M; Perrier L; Pommier P; Boisselier P; Coche-Dequéant B; Gallocher O; Alfonsi M; Bardet É; Rives M; Calugaru V; Chajon E; Noël G; Mecellem H; Pérol D; Dussart S; Giraud P
Cancer Radiother; 2016 Jul; 20(5):357-61. PubMed ID: 27345843
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Kataoka T; Kiyota N; Shimada T; Funakoshi Y; Chayahara N; Toyoda M; Fujiwara Y; Nibu K; Komori T; Sasaki R; Mukohara T; Minami H
Auris Nasus Larynx; 2016 Dec; 43(6):677-84. PubMed ID: 26992271
[TBL] [Abstract][Full Text] [Related]
35. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
Acevedo-Henao CM; Valette G; Miglierini P; Lefur E; Pradier O
Cancer Radiother; 2012 Oct; 16(7):601-3. PubMed ID: 23089070
[TBL] [Abstract][Full Text] [Related]
37. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer.
Huang J; Baschnagel AM; Chen P; Gustafson G; Jaiyesmi I; Folbe M; Ye H; Akervall J; Krauss D
Int J Clin Oncol; 2014 Apr; 19(2):240-6. PubMed ID: 23479120
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
[TBL] [Abstract][Full Text] [Related]
40. Complication and surgical site infection for salvage surgery in head and neck cancer after chemoradiotherapy and bioradiotherapy.
Suzuki H; Hanai N; Nishikawa D; Fukuda Y; Hasegawa Y
Auris Nasus Larynx; 2017 Oct; 44(5):596-601. PubMed ID: 28043710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
